Experimental drug flotetuzumab tested in just 3 patients for relapsed AML

NCT ID NCT05506956

Completed Disease control Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This early-phase study tested the safety of a drug called flotetuzumab in 3 adults with acute myeloid leukemia (AML) that had returned after a stem cell transplant. The drug targets a protein on leukemia cells and was given as a continuous infusion. The main goal was to find a safe dose, not to prove the drug works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: flotetuzumab
What this could lead to: If it works, this could point toward a treatment for AML that has relapsed after transplant.
What could go wrong: This is a very early, tiny phase 1 trial with only 3 participants. It focuses on safety, not effectiveness, and may not lead to a proven treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LEUKEMIA, MYELOID, ACUTE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LEUKEMIA, MYELOID, ACUTE

Contacts and locations

Locations

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Baltimore, Maryland, 21231, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.